Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02869633
Title Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

mantle cell lymphoma

follicular lymphoma

Hodgkin's lymphoma

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST